Clinical Scorecard: Therapeutic Focus: Digital Patching for Amblyopia
At a Glance
| Category | Detail |
|---|---|
| Condition | Amblyopia linked with anisometropia and/or mild strabismus |
| Key Mechanisms | Digital patching via blurring dominant eye's center vision to stimulate amblyopic eye; eye-tracking and anaglyph red-blue glasses |
| Target Population | Patients aged 4 to 9 years with best-corrected visual acuity of 20/100 or better and strabismus limited to tropia ≤5 prism diopters |
| Care Setting | Pediatric ophthalmology and eyecare clinics with remote monitoring capabilities |
Key Highlights
- CureSight is FDA-approved for improving visual and stereo acuity in amblyopia associated with anisometropia and mild strabismus.
- Treatment involves 30 hours per 30-day cycle, recommended for at least 6 months, with remote monitoring and data delivery to providers.
- Contraindicated in patients with light-induced epilepsy and less suitable for those with limited attention span or parental concerns about screen time.
Guideline-Based Recommendations
Diagnosis
- Confirm amblyopia with anisometropia and/or mild strabismus (tropia ≤5 prism diopters).
- Ensure best-corrected visual acuity is 20/100 or better.
Management
- Use CureSight digital patching platform with refractive correction worn under treatment glasses.
- Recommend 30 hours of treatment per 30-day cycle over at least 6 months.
- Employ CPT codes 0704T for remote installation/training, 0705T for treatment monitoring, and 0706T for remote adherence monitoring.
Monitoring & Follow-up
- Schedule follow-up visits every 3 months (90 days) for clinical assessment.
- Use CPT 92012 for monitoring established patients.
- Designate a treatment coordinator to connect caregivers with NovaSight and monitor patient use.
Risks
- Avoid use in patients with history of light-induced epilepsy.
- Consider patient attention span and parental comfort with screen time before initiating treatment.
Patient & Prescribing Data
Children aged 4 to 9 years with amblyopia due to anisometropia and/or mild strabismus
Improvements noted in visual acuity, stereoacuity, Randot stereotesting, and Worth 4 Dot testing; can be used as first-line therapy or adjunct to refractive correction.
Clinical Best Practices
- Incorporate refractive correction during treatment sessions under the provided glasses.
- Engage patients by integrating favorite streaming content to enhance visual engagement and adherence.
- Utilize remote monitoring and data reporting to optimize treatment adherence and outcomes.
- Educate caregivers thoroughly and provide a dedicated coordinator for support and setup.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.